Results. Among the 44 participants, mean age is 40 years; 73% are males; 48% Hispanic, 38% non-Hispanic white; 7% non-Hispanic black and 7% mixed-race or other. Almost all (96%) had health insurance, with 86% having public insurance (Medicaid). Most participants (91%) were aware of their HCV diagnosis before enrollment. All wanted to be treated for HCV, and 88% wanted treatment to prevent infecting others. 48% had previously been referred for HCV treatment, only 21% had been offered treatment, and none had started. When asked about barriers to treatment, 56% participants felt that they would need to stop using drugs to get HCV treatment, 61% felt that HCV treatment had many side effects and 20% reported insurance coverage barriers.
Background. Hepatitis C virus (HCV) infection has received significant attention in recent years due to the ability for near universal cure, the price of therapy, and increasing incidence due to injection drug use. While the discussion largely focuses on HCV infection in adults, children with HCV are a consistent minority of patients with long-term adverse outcomes of HCV. Few studies have defined the healthcare utilization of HCV-infected children.
Objective: To define trends in pediatric HCV cases and healthcare utilization using a national administrative database.
Methods. The Pediatric Health Information Systems (PHIS) database contains inpatient encounter-level data from tertiary care pediatric hospitals in the United States. We identified pediatric HCV cases using validated ICD-9/ICD-10 diagnosis codes (070.41, 070.44, 070.51, 070.54, 070.70, 070.71, V0262, B18.2) . We evaluated total cases identified, year of presentation, patient age, geographic location by state, aggregate cost of providing care and HIV-coinfection (ICD-9 code 042/ICD-10 code B20).
Results. Since 1992, there were 2,175 unique pediatric patients identified with HCV infection. Case rates were highest in patients 15-17 years with a peak of 24 cases/10,000 admissions that fell to 10 cases /10,000 in 2,000 and a low of 1 case/10,000 in 2015. Alarmingly, the rate in this group was back over two cases/10,000 in 2016 and 2017. HCV case rates in children 11-14 were the second highest with more sustained peak from 1992 to 2006 and no precipitous decline. There were 49 patients with HIV co-infection, with rates highest prior to 1998 (range of 6.5-18%), but since 2002 have been <2% until 2017 (2.5%). For inpatient costs, 10% of HCV infected children accounted for 75% of the total cost of care. In 2004-2006, total charges for 329 HCV-infected children were just over $23 million, compared with 2015-2017 when total charges for 247 HCV-infected children were $21.8 million. Comparing these two eras and adjusting for inflation, there was a 3% decline in charges per patient.
Conclusion. While the burden of inpatient HCV in children has declined since the peak in the early 1990s, there are worrisome increases detected in the last few years. A small minority of patients represent a disproportional amount of the total care provided. Early treatment of children would still likely prove cost-effective.
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Low Hepatitis C Treatment Rates Among Patients Screened as Inpatients at a Rural Academic Medical Center

Methods.
Results. In 2016, 504 inpatients at DHMC were screened with an HCV antibody test, of which 65 (13%) were positive. Of these, 50 (77%) had follow-up HCV RNA testing, resulting in 38 (76%) patients with detectable viremia. Of the 53 patients with detected (38) or unknown viremia (15), five died on the index admission, one was discharged to a hospice, 16 were referred to the DHMC hepatology (GI) clinic and 11 to the DHMC infectious disease (ID) clinic, but 20 received no referral. Thirty-two (60%) patients had an active SUD, and 7 (13%) were in remission.
Through December 31, 2017, 15 (31%) of the surviving 48 patients had no further follow-up in the Dartmouth-Hitchcock Health System. Fourteen (29%) patients followed up in the GI clinic, 11 (23%) followed up in the ID clinic and 8 (17%) had subsequent encounters in clinics for conditions other than HCV. Only 5 (10%) patients were treated for HCV and achieved sustained virologic response (SVR), all of which had followed up in the GI clinic. The odds of follow-up or treatment were independent of a history of SUD. Providers frequently deferred treatment due to ongoing substance use or a focus on more urgent medical issues. Insurance coverage for direct-acting antivirals was evolving during the study period, preventing treatment in some patients.
Conclusion. Only 10% of patients screened positive for HCV during an inpatient admission to a rural academic medical center received treatment for HCV in the year following their diagnosis. Linkage to care, patient engagement and provider perceptions have to improve to achieve elimination of HCV.
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Treatment Uptake for Hepatitis C Virus Infection in the Veterans
Results. A total of 108,133 persons were initiated on treatment (Figure 1 ). Sofosbuvir-based regimens were the most commonly used regimens, accounting for nearly two-thirds of all DAA regimens. Gastroenterologists/hepatologist were the most common initiators of treatment in the pre-DAA era accounting for 26. Conclusion. There has been a dramatic increase in HCV treatment uptake in the VA healthcare system with the approval of newer all-oral DAA regimens. Treatment paradigm appears to be shifting toward lesser gastroenterologists/hepatologists and more allied health professionals treating HCV. 
